Clin Osteol 2019; 24(3): 93-100

Osteoporosis in men: what changed?Review articles

Tomková Soňa; Vrško Martin
Interná klinika LF UPJŠ a Nemocnice Košice-Šaca, Košice

Osteoporosis, in which the bones become porous and break easily, is one of the world´s most common and debilitating diseases. The lifetime risk for osteoporotic fracture in older men may range from 13 to 25 %. Although it affects men less commonly than woman, men who do sustain fractures may suffer more severely in terms of the quality and quantity of their lives than when fractures occur in woman. Unfortunately, lack of doctors are not aware of the problem of osteoporosis in men, and the identification of people at risk is far from being a standard practice. Osteoporosis can, to a certain extent, bez prevented, it can be easily diagnosed and effective treatments are available, let´s make a choice.

Keywords: classification; Epidemiology; osteoporosis in men

Received: July 18, 2019; Accepted: August 12, 2019; Published: December 11, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomková S, Vrško M. Osteoporosis in men: what changed? Clinical Osteology. 2019;24(3):93-100.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bliuc D, Nguyen ND, Milch VE et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and woman. JAMA 2009; 301(5): 513-521. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2009.50>. Go to original source...
    2. Adler RA. Update on osteoporosis in men. Best Pract Res Clin Endocrinol Metab 2018; 32(5): 759-772. Dostupné z DOI: <http://dx.doi.org/10.1016/j.beem.2018.05.007>. Go to original source...
    3. Solomon DH, Johnston SS, Boytsov NN et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 2014; 29(9): 1929-1937. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.2202>. Go to original source...
    4. Jennings LA, Auerbach AD, Maselli J et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture, J Am Geriatr Soc 2010; 58(4): 650-657. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1532-5415.2010.02769.x>. Go to original source...
    5. Hopkins RB, Pullenayegum E, Goeree R et al. Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int 2012; 23(3): 921-927. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-011-1652-8>. Go to original source...
    6. Pasco JA, Lane SE, Brennan SL et al. Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data. Osteoporos Int 2014; 25(3): 857-862. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-013-2561-9>. Go to original source...
    7. Wright NC, Saag KG, Dawson-Hughes B et al. The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. Osteoporos Int 2017; 28(11): 1225-1232. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-017-4207-9>. Go to original source...
    8. Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med 1986; 314(26): 1676-1686. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM198606263142605>. Go to original source...
    9. Harman SM, Metter EJ, Tobin JD et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001; 86(2): 724-731. Dostupné z DOI: <http://dx.doi.org/10.1210/jcem.86.2.7219>. Go to original source...
    10. Adler RA. Osteoporosis in men: insights for the clinician. Ther Adv Musculoskel Dis 2011; 3(4): 191-200. Dostupné z DOI: <http://dx.doi.org/10.1177/1759720X11411600>. Go to original source...
    11. Rosen CJ, Kurland ES, Vereault D et al. Association between serum IGF-I and a simple sequence repeat inf the IFG-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998; 83(7): 2286-2290. Dostupné z DOI: <http://dx.doi.org/10.1210/jcem.83.7.4964>. Go to original source...
    12. Ebeling PR. Clinical practice. Osteoporosis in men. J Eng J Med 2008; 358(14): 1474-1482. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMcp0707217>. Go to original source...
    13. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23(34): 8580-8587. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2005.02.8670>. Go to original source...
    14. Antonio L, Wu FCV, O´Neil TW et al. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab 2016; 101(7): 2647-2657. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2015-4106>. Go to original source...
    15. Khosla S, Melton LJ, Atkinson EJ et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86(8): 3555-3561. Dostupné z DOI: <http://dx.doi.org/10.1210/jcem.86.8.7736>. Go to original source...
    16. Javaid MK, Cooper C. Prenatal and childhood influences on osteoporosis. Best Pract res Clin Endocrinol Metab 2002; 16(2): 349-367. Dostupné z DOI: <http://dx.doi.org/10.1053/beem.2002.0199>. Go to original source...
    17. Snyder PJ, Kopperdahl DL, Stephens-Shields AJ et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone. A controlled clinical trial. JAMA Intern Med 2017; 177(4): 471-479. Dostupné z DOI: <http://dx.doi.org/10.1001/jamainternmed.2016.9539>. Go to original source...
    18. Watts NB, Adler RA, Bilezikian JP et al. Osteoporosis in men: an endocrine society clinical practice guidelines. J Clin Endocrinol Metab 2012; 97(6):1802-1822. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011-3045>. Go to original source...
    19. Alswat KA. Gender Disparities in Osteoporosis. J Clin Med Res 2017; 9(5): 382-387. Dostupné z DOI: <http://dx.doi.org/10.14740/jocmr2970w>. Go to original source...
    20. Mackey DC, Lui LY, Cawthon PM et al. High-trauma fractures and low bone mineral density in older women and men. JAMA 2007; 298(20): 2381-2388. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.298.20.2381>. Go to original source...
    21. van Staa TP, Leufkens HGM, Abenheim I et al. Oral corticosteroids and fracture risk: relationship to daily nad cumulative doses. Rheumatology (Oxford) 2000; 39(12): 1383-1389. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/39.12.1383>. Go to original source...
    22. Waljee AK, Rogers MA, Lin P et al. Short term use of oral corticosteroids nad related harms among adults in the United States: population based cohort study. BMJ 2017; 357: j1415. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.j1415>. Go to original source...
    23. Kaze AD, Rosen HN, Paik JM. A meta-analysis of teh association between body mass index and risk of vertebral fracture. 2018; 29(1): 31-39. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-017-4294-7>. Go to original source...
    24. Jean S, O´Donnell S, Lagace C et al. Trends in hip fracture rates In Canada: an age-period-cohort analysis. J Bone Miner Res 2013; 28(6): 1283-1289. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1863>. Go to original source...
    25. Khosla S, Shane E. A crisis in the treatment of osteoporosis. J Bone Miner Res 2016; 31(8): 1485-1487. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.2888>. Go to original source...
    26. Odborné usmernenie MZ SR pre diagnostiku a liečbu osteoporózy 2006. Dostupné z WWW: <http://www.osteoporoza.sk/fileadmin/osteoporoza/lekari/Guidelines_a_knihy/Vestnik_MZSR_-_osteoporoza.pdf>.
    27. Chaganti RK, Parimi N, Lang T et al. Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporotic Fractures in Men (MrOS) Study Group. Osteoporos Int 2010; 21(8): 1307-1316. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-009-1105-9>. Go to original source...
    28. Orwoll E, Teglbjaerg CS, Langdahl BL et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. J Clin Endocrin Metab 2012; 97(9): 3161-3169. Dostupné z DOI: <https://doi.org/10.1210/jc.2012-1569>. Go to original source...
    29. Orwoll E, Teglbjaerg CS, Langdahl BL et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. J Clin Endocrin Metab 2012; 97(9): 3161-3169. Dostupné z DOI: <https://doi.org/10.1210/jc.2012-1569>. Go to original source...
    30. Tomková S, Beličáková Z. Osteoporóza u mužov. Via Pract 2009; 6(9): 350-352.
    31. Orwoll E ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343(9): 604-610. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200008313430902>. Go to original source...
    32. Ringe JD, Faber H, Farahmand P et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006; 26(5): 427-431. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296-005-0004-4>. Go to original source...
    33. Zoznam kategorizovaných liekov 1. 7. 2019-31. 7. 2019. Časť B: indikačné obmedzenia. Ministerstvo zdravotnícka Slovenskej republiky. Dostupné z WWW: <https://www.health.gov.sk/Clanok?lieky201907>.
    34. Boonen S, Reginster JY, Kaufman JM et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367(18): 1714-1723. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1204061>. Go to original source...
    35. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22(10): 1479-1491. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.0707onj>. Go to original source...
    36. Shane E, Burr D, Abrahamsen B et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29(1): 1-23. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1998>. Go to original source...
    37. Unnanuntana A, Jarusriwanna A, Songcharoen P. Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax). PLoS One 2017; 12(7): e0180325. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0180325>. Go to original source...
    38. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296(24): 2927-2938. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.296.24.2927>. Go to original source...
    39. Black DM, Reid IR, Boonen S et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27 : 243-254. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1494>. Go to original source...
    40. Langdahl B, Teglbjaerg CS, Ho PR et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 2015; 100(4): 1335-1342. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014-4079>. Go to original source...
    41. Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361(8): 745-755. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0809003>. Go to original source...
    42. Kendler DL, Roux C, Benhamou CL et al. Effects of denosumab on bone mineral density and bone turnover in post-menopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25(1): 72-81. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.090716>. Go to original source...
    43. Anastasilakis AD, Polyzos SA, Makras P et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017; 32(6): 1291-1296. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.3110>. Go to original source...
    44. Orwoll ES, Shceele WH, Paul S et al. The effect of teriparatide (human parathyroid hormone 1-34) therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18(1): 9-17. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.2003.18.1.9>. Go to original source...
    45. Miller PD, Hattersley G, Riis BJ et al. Effects of abaloparatide on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016; 316(7): 722-733. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.11136>. Go to original source...
    46. Kaufman JM, Orwoll E, Goemaere S et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: 36 month results. Osteoporos Int 2005; 16(5): 510-516. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-004-1713-3> Go to original source...
    47. Crandal CJ, Newberry SJ, Diamant A et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 2014; 161(10): 711-723. Dostupné z DOI: <http://dx.doi.org/10.7326/M14-0317>. Go to original source...
    48. Center JR, Bliuc D, Nguyen TV et al. Risk of subsequent fracture after low-trauma fracture in men and woman. JAMA 2007; 297(4): 387-394. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.297.4.387>. Go to original source...
    49. Bliuc D, Center JR. Determinants of mortality risk following osteoporotic fractures. Curr Opin Rheumatol 2016; 28(4): 413-419. Dostupné z DOI: <http://dx.doi.org/10.1097/BOR.0000000000000300>. Go to original source...
    50. Payer J, Killinger Z. Osteroporóza. Herba: Bratislava 2012. ISBN 978-80-89171-84-1.
    51. Kanis JA, Borgstrom F, Compston J et al. SCOPE: a scorecard of osteoporosis in Europe. Arch Osteoporos 2013; 8 : 144. Dostupné z DOI: <http://dx.doi.org/10.1007/s11657-013-0144-1>. Go to original source...
    52. Herrea A, Lobo-Escolar A, Mateo J et al. Male osteoporosis: A review. World J Orthop 2012; 3(12): 223-234. Dostupné z DOI: <http://dx.doi.org/10.5312/wjo.v3.i12.223>. Go to original source...
    53. Tomková S,Telepková D. Sekundárna osteoporóza. Via Pract 2005; 2(11): 446-449.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.